Search

Experimental data on the effectiveness of p-brombenzothiohydroximic S-diethylaminoethylate (diethyxime) -a new cholinesterase reactivator - are presented. The diethyximetoxicity with its single and multiple administration to animals was studied. The drug is shown to display a marked antidotal action when used in a dosage range of 490-10 mg/kg. Diethyxime is shown capable of restoring the activity of cholinesterase inhibited by dimethyldichlorovenylphosphate, of preventing the neuro-muscular block of the impulses conduction and of normalizing the function of the cardiovascular system. The drug is less toxic than is presently employed reactivator diproxime and it does not produce any side-effects on a number of organs and systems of the organism with its multiple administration to worm-blooded animals.

The effect of a new cholinolytic drug ethpenal, that is applied clinically as an antiparkinsonian and antiulcer agent, on the course of experimental myocardial infarction has been studied. The experiments have shown that in the test animals (white rats and rabbits) with myocardial infarction, ethpenal increases by 9.3% the contractile function of myofibrils, makes tissue respiration return to normal, and approximates the P/O magnitude to the control level. Administration of ethpenal to the animals with experimental myocardial infarction induces a considerable increase in the content of polyglycerophosphatides, which, in its turn, leads to stabilization of the cellular membranes. The drug improves permeability of the bilayer lecithin membranes by calcium ions. A conclusion is made that the myocardial infarction, ethpenal exerts a beneficial effect on the processes occurring at a level of the cellular membranes.